Abstracts

467 – Longitudinal High-Dimensional Proteomics Reveals Evolving CNS Immune Dysfunction During Early HIV

Background PWH typically start ART years after acquiring HIV, however understanding of the natural history of CNS pathobiology during early infection prior to ART is limited.  We examined cerebrospinal fluid (CSF) samples from PWH recruited during primary HIV infection (PHI, <1 year since HIV acquisition) followed longitudinally prior to ART initiation to interrogate the early…

427 – Safety and Viral Dynamics During Temporary Treatment Interruption (TTI) in the RV630 HIV Cure Trial

Background Temporary treatment interruption (TTI) is a novel strategy in which antiretroviral therapy (ART) is stopped to allow viral reactivation and transient viremia under close monitoring. In HIV cure trials that include broadly neutralizing antibodies (bNAbs) or therapeutic vaccines, TTI allows formation of antigen-antibody immune complexes and primes B and T cells with participant-specific antigen…

786 – Impact of Rifabutin on Bictegravir Ctrough and Viral Control in PWH With Mycobacterial Infection

Background Mycobacterial infection is an important opportunistic infection in people with HIV (PWH), which often requires rifamycin-containing anti-mycobacterial therapy. Rifabutin (RFT), a cytochrome P450 3A4 inducer, may significantly reduce bictegravir trough concentrations (BIC Ctrough), but the impact of this drug-drug interaction on viral control is rarely assessed. Methods This prospective multi-center study enrolled PWH receiving…

826 – Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF) in Pregnant People Living With HIV (PLHIV)

Background Because there are >1 million pregnant PLHIV globally, many of whom receive antiretroviral therapy (ART) to prevent vertical transmission, a large population of HIV-exposed uninfected (HEU) children exists. HEU infants face increased severe RSV-associated lower respiratory tract illness (RSV-LRTI) rates compared to unexposed infants. The pivotal MATISSE trial demonstrated that maternal RSVpreF vaccination can…

334 – Acute Bacterial STIs Enhance HIV-1 Reservoir Reactivation and Immune Dysregulation in PLWH

Background The persistent HIV-1 reservoir in CD4+ T cells remains the major obstacle to cure, yet the mechanisms regulating reservoir reactivation and immune surveillance are not fully understood. Sexually transmitted infections (STIs) induce mucosal inflammation and systemic immune activation that may alter reservoir dynamics and compromise HIV-specific immune responses. We therefore analysed how acute bacterial…

884 – Causal Forecasting of Regional Opportunistic Infections With Improved Insurance Coverage Simulations

Background Opportunistic infections (OIs) remain a significant cause of morbidity among people with HIV (PWH) in the US. National trends may mask important regional variations in OI burden that could inform targeted interventions. We analyzed historical and forecasted OI-related hospitalization rates among PWH including estimated costs per US Region and simulated changes to these with…

630 – HHV-8 Viral Load as Predictor for Cutaneous+Visceral Kaposi Sarcoma in PLWH: Multivariable Analysis

Background Kaposi Sarcoma (KS) is a significant cause of morbidity and mortality in PLWH. While cutaneous involvement is common, visceral only or cutaneous+visceral disease confer poor prognosis. The utility of human herpesvirus-8 (HHV-8) viral load (VL) as a predictor of visceral involvement remains poorly characterized. In this study, we aimed to determine the clinical diagnostic…

896 – HIV Seroconversion and Associated Risk in a Transgender and Nonbinary Cohort in Argentina

Background Transgender women (TGW) are disproportionately affected by HIV worldwide, but prospective incidence data from Latin America are scarce. We estimated HIV incidence, cumulative risk of seroconversion, and associated factors in a TGW cohort in Argentina. Methods Between September 2019 and August 2022, 499 transgender and non-binary individuals (TNB) were enrolled in a prospective cohort.…

1090 – Removing Insurance Barriers to Oral PrEP Reduces HIV Cases and Costs in Underserved US Populations

Background HIV-1 continues to impose unequal burdens in US communities. Incidence rates remain elevated among Black and Hispanic men who have sex with men (MSM), transgender women (TGW), and cisgender women (CGW) with PrEP indications. Insurance barriers, e.g. prior authorization and coverage restrictions, hinder PrEP access and often lead to PrEP abandonment in these underserved populations. Tao…